Author name: Immunwork Web Team

Our Core Technology Platform Published in the Journal of the Chinese Chemical Society

Scientific Publication /

T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform “Multi-Arm Linkers”, highlighting its innovative design and broad applications in novel drug development. JCCS is one of Taiwan’s longest-established SCI-indexed chemistry journals. It is published by the Chemical Society […]

Our Core Technology Platform Published in the Journal of the Chinese Chemical Society Read More »

T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026

News /

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock

T-E Pharma Launches Pre-IPO Capital Raise Pursuing a Dual-Engine Strategy in Metabolic and Oncology Therapeutics; Targeting TPEx Emerging Stock Board Listing in Q4 2026 Read More »

Our Latest Research Published in International Journal of Pharmaceutics

Scientific Publication /

Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published

Our Latest Research Published in International Journal of Pharmaceutics Read More »

Join our presentation at the BIOLOGICS WORLD TAIWAN 2026

Meeting /

We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by the international

Join our presentation at the BIOLOGICS WORLD TAIWAN 2026 Read More »

T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones

News /

T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with

T-E Pharma Hosts Annual Year-End Gala as Five Drug Candidates Reach Key Development Milestones Read More »

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship

Reported /

Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable

An Interview with Chairman Tse-Wen Chang, Founder of Immunwork and T-E Meds: A Journey Through Science and Entrepreneurship Read More »

Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution”

Reported /

In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings. Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for

Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution” Read More »

Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential

R&D Progress /

Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), TE-8105, developed for the treatment of obesity. Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse

Immunwork Announces Positive Phase 1/2a Results for TE-8105, a Long-Acting GLP-1 RA, Demonstrating Favorable Safety, Tolerability, and Weight-loss Potential Read More »

In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology

Reported /

T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of only six companies worldwide to be shortlisted for the “Best New Drug Developer 2025” category at the 12th World ADC Awards. This recognition highlights T-E Meds’ outstanding achievements in ADC technology platforms and innovative drug

In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology Read More »

Scroll to Top